ERBB2 and non-small cell lung carcinoma: The phase 2 clinical trail of Li et al. have supported the clinical benefit of trastuzumab deruxtecan in patients with HER2-mutant NSCLC, while 49% of patients had drug-related grade 3 or higher adverse events which must be carefully monitored [13].